• 1
    Geiger HJ. Race and health care—an American dilemma? N Engl J Med 1996; 335: 815816.
  • 2
    Qualheim RE, Rostand SG, Kirk KA, Rutsky EA, Luke RG. Changing patterns of end-stage renal disease due to hypertension. Am J Kidney Dis 1991; 18: 336343.
  • 3
    Rostand SG. US minority groups and end-stage renal disease: a disproportionate share. Am J Kidney Dis 1992; 19: 411413.
  • 4
    Renal Data System USRDS 1996 Annual Data Report. Bethesda , MD , USA : National Institute of Diabetes and Digestive and Kidney Diseases , 1996.
  • 5
    Opelz G, Mickey MR, Terasaki PI. Influence of race on kidney transplant survival. Transplant Proc 1977; 9: 137142.
  • 6
    Curtis JJ. Kidney transplantation: racial or socioeconomic disparities? Am J Kidney Dis 1999; 34: 756758.
  • 7
    Isaacs RB, Nock SL, Spencer CE et al. Racial disparities in renal transplant outcomes. Am J Kidney Dis 1999; 34: 706712.
  • 8
    OPTN-SRTR 2003 Annual Report. Available at:
  • 9
    Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med 2000; 343: 15451552.
  • 10
    Lindholm A, Welsh M. Alton C, Kahan BD. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52: 359371.
  • 11
    David RJ, Collins JW Jr. Differing birth weight among infants of U.S.-born blacks, African-born blacks, and U.S.-born whites. N Engl J Med 1993; 337: 12091214.
  • 12
    First MR, Schroeder TJ, Monaco AP, Simpson MA, Curtis JJ, Armenti VT. Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant 1996; 10: 5559.
  • 13
    Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64: 12771282.
  • 14
    Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515523.
  • 15
    Cosio FG, Dillon JJ, Falkenhain ME et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995; 47: 11361141.
  • 16
    Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178185.
  • 17
    Basadonna GP, Matas AJ, Gillingham KJ et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993995.
  • 18
    Posner MP, McGeorge MB, Mendez-Picon G, Mohanakumar T, Lee HM. The importance of the Lewis system in cadaver renal transplantation. Transplantation 1986; 41: 474477.
  • 19
    Butkus DE, Dottes AL, Meydrech EF, Barber WH. Effect of poverty and other socioeconomic variables on renal allograft survival. Transplantation 2001; 72: 261266.
  • 20
    Sanders CE, Curtis JJ, Julian BA et al. Tapering or discontinuing cyclosporine for financial reasons—a single-center experience. Am J Kidney Dis 1993; 21: 915.
  • 21
    Yen EF, Hardinger K, Brennan DC et al. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant 2004; 4: 17031708.
  • 22
    Adams J, Ward RH. Admixture studies and the detection of selection. Science 1973; 180: 11371143.
  • 23
    Chakraborty R, Kamboh MI, Ferrell RE. ‘Unique’ alleles in admixed populations: a strategy for determining ‘hereditary’ population differences of disease frequencies. Ethn Dis 1991; 1: 245256.
  • 24
    Glass B, Li CC. The dynamics of racial intermixture—an analysis based on the American Negro. Am J Hum Genet 1953; 5: 120.
  • 25
    Reed TE. Caucasian genes in American Negroes. Science 1969; 165: 762768.
  • 26
    Cockcroft RW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 27
    Butkus DE, Meydrech MF, Raju SS. Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992; 327: 840845.
  • 28
    Kasiske BL, Neylan JF III, Riggio RR et al. The effect of race on access and outcome in transplantation. N Engl J Med 1991; 324: 302307.
  • 29
    Cecka JM. The UNOS Scientific Renal Transplant Registry. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1998. Los Angeles : UCLA Tissue Typing Laboratory , 1999: 116.
  • 30
    Gaston RS, Hudson SL, Deierhoi MH et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 1992; 53: 103109.
  • 31
    Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD. Possible contribution of pretransplant immune responder status to renal allograft survival differences of blacks versus white recipients. Transplantation 1991; 51: 33842.
  • 32
    Thervet E, Anglicheau D, King B et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 12331235.
  • 33
    Oriol R, Le Pendu J, Chun C. Influence of the original disease, race, and center on the outcome of kidney transplantation. Transplantation 1982; 33: 2226.
  • 34
    Terasaki PI, Cecka JM, Gjertson DW, Takemoto S, Cho YW, Yuge J. Risk rate and long-term kidney transplant survival. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1996. Los Angeles : UCLA Tissue Typing Laboratory , 1997: 443458.
  • 35
    De Geest S, Borgermans L, Gemoets H et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995; 59: 340347.
  • 36
    Gornick ME, Eggers PW, Reilly TW et al. Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med 1996; 335: 791799.
  • 37
    Woodward RS, Schnitzler MA, Lowell JA et al. Medicare's extended immunosuppression coverage improved graft survival (abstract). J Am Soc Nephrol 1999; 10: 751A.
  • 38
    Sanders CE, Julian BA, Gaston RS, Deierhoi MH, Diethelm AG, Curtis JJ. Benefits of continued cyclosporine through an indigent drug program. Am J Kidney Dis 1996; 28: 572577.
  • 39
    Chakkera HA, O'Hare AM, Johansen KL et al. Influence of race on kidney transplant outcomes within and outside the Department of Veterans Affairs. J Am Soc Nephrol 2005; 16: 269277.